Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
Publication/Presentation Date
7-1-2009
Abstract
Cancer patients are at high-risk of venous thromboembolism (VTE). However, the optimal VTE prophylaxis and treatment options for this population are currently unclear. Surgical cancer patients have been shown to benefit from pharmacological VTE prophylaxis, with a number of trials suggesting that prophylaxis duration should extend beyond the traditional 7 day period. Medical (nonsurgical) cancer patients are also at high-risk of VTE, and evidence-based guidelines recommend pharmacological VTE prophylaxis in hospitalized cancer patients who are bedridden. In cancer patients with confirmed VTE, questions remain over the most effective long-term treatment regimen. Further trials are required to help physicians to make evidence-based choices for the management of VTE in these patients.
Volume
74 Suppl 1
First Page
27
Last Page
34
ISSN
1522-726X
Published In/Presented At
Merli G. J. (2009). Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 74 Suppl 1, S27–S34. https://doi.org/10.1002/ccd.22089
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
19530157
Department(s)
Administration and Leadership
Document Type
Article